Bengaluru-based Indian biopharmaceutical company Plasmagen Biosciences Private Limited (Plasmagen), which specialises in plasma protein and specialty care therapy has launched Haemocomplettan P (Human Fibrinogen Concentrate). Leader in the field of biotechnology worldwide CSL Behring produces this product, which Plasmagen will only market in India. Haemocomplettan P is now licenced by Plasmagen to treat and prevent hemorrhagic diatheses in acquired hypofibrinogenemia and congenital afibrinogenemia.

Hemocomplettan P is intended to successfully manage bleeding during Indian heart and liver transplant procedures. Such therapies are much needed in the nation, where about 1,50,000 heart procedures and 1,800 liver transplants are performed annually.

Fibrinogen is important in surgical settings, according to Dr. N. Kanagarajan, Senior Consultant Cardiac Anaesthesiologist at the Madras Medical Mission in Chennai. "Human fibrinogen concentrate (HFC) has demonstrated efficacy in restoring fibrinogen levels, offering potential benefits in reducing bleeding and minimising the need for intraoperative blood transfusions," the statement said. "Fibrinogen plays a pivotal role in cardiac surgery bleeding, with decreased concentrations contributing to adverse outcomes."

The frequency of uncontrollably large bleeding during these procedures emphasises the need of hemocomplettan P and similar medicines. Controlling bleeding too slowly after heart surgery can have serious consequences including stroke, myocardial injury or death, and much higher medical expenses. Prolonged ICU and hospital stays, more septic episodes, and greater death rates can all arise from severe bleeding and blood transfusion after liver transplant procedures. Haemocomplettan P facilitates replacement therapy for those who are bleeding profusely and are deficient in fibrinogen, therefore stopping bleeding rapidly.

Commenting on the partnership with CSL Behring was Plasmagen Biosciences' Managing Director, Vinod Nahar. "The partnership between Plasmagen and CSL Behring will guarantee availability to high-quality products meeting international safety requirements in the biopharmaceutical industry in addition to creating new opportunities in several specialties, including as cardiac, liver transplant, gastroenterology, and paediatrics. We are dedicated to offer complete solutions for patient education, disease knowledge, and therapy shaping," he declared.

Purified human fibrinogen concentrate Haemocomplettan P has been treating more than 3.5 lakh patients globally for over 27 years. Hemostattan P is positioned to be crucial in enhancing patient outcomes in India because of the high incidence of uncontrolled severe bleeding during cardiac and liver transplant procedures.

Launching Hemocomplettan P in India is seen as a major step towards solving the unmet medical needs in the nation's healthcare system, particularly for patients having major operations. By offering a dependable and efficient course of therapy, Plasmagen and CSL Behring want to improve the standard of treatment and lower the cost of surgical complications.

The release of Haemocomplettan P highlights the need of cutting-edge treatment choices in treating complicated medical diseases as the biopharmaceutical scene in India changes. Both patients and healthcare professionals should eventually gain from this effort as it opens the door for more breakthroughs and partnerships in the industry.